Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Aug, 2016 | Pages:
427 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Bone Marrow Transplant Rejection - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Bone Marrow Transplant Rejection - Pipeline Review, H2 2016', provides an overview of the Bone Marrow Transplant Rejection pipeline landscape. The report provides comprehensive information on the therapeutics under development for Bone Marrow Transplant Rejection, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bone Marrow Transplant Rejection and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Bone Marrow Transplant Rejection - The report reviews pipeline therapeutics for Bone Marrow Transplant Rejection by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Bone Marrow Transplant Rejection therapeutics and enlists all their major and minor projects - The report assesses Bone Marrow Transplant Rejection therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Bone Marrow Transplant Rejection Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Bone Marrow Transplant Rejection - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Bone Marrow Transplant Rejection pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 7 List of Figures 9 Introduction 10 Global Markets Direct Report Coverage 10 Bone Marrow Transplant Rejection Overview 11 Therapeutics Development 12 Pipeline Products for Bone Marrow Transplant Rejection - Overview 12 Pipeline Products for Bone Marrow Transplant Rejection - Comparative Analysis 13 Bone Marrow Transplant Rejection - Therapeutics under Development by Companies 14 Bone Marrow Transplant Rejection - Therapeutics under Investigation by Universities/Institutes 19 Bone Marrow Transplant Rejection - Pipeline Products Glance 21 Late Stage Products 21 Clinical Stage Products 22 Early Stage Products 23 Unknown Stage Products 24 Bone Marrow Transplant Rejection - Products under Development by Companies 25 Bone Marrow Transplant Rejection - Products under Investigation by Universities/Institutes 31 Bone Marrow Transplant Rejection - Companies Involved in Therapeutics Development 33 AbbVie Inc 33 AbGenomics International, Inc. 34 Actelion Ltd 35 Alexion Pharmaceuticals Inc 36 Amunix Operating Inc. 37 Apceth GmbH & Co. KG 38 arGEN-X BV 39 Athersys, Inc. 40 Bellicum Pharmaceuticals, Inc. 41 Bio-Cancer Treatment International Limited 42 Biogen Inc 43 Boryung Pharmaceutical Co., Ltd. 44 Bristol-Myers Squibb Company 45 Cantex Pharmaceuticals, Inc. 46 Capricor Therapeutics, Inc. 47 Cell Source, Inc. 48 Cell2B S.A. 49 CellECT Bio, Inc. 50 Cleveland BioLabs, Inc. 51 Compugen Ltd. 52 Cynata Therapeutics Limited 53 Cytodyn Inc. 54 Dompe Farmaceutici S.p.A. 55 Dr. Falk Pharma GmbH 56 Escape Therapeutics, Inc. 57 F. Hoffmann-La Roche Ltd. 58 Fate Therapeutics, Inc. 59 Generon (Shanghai) Corporation Ltd. 60 Gilead Sciences, Inc. 61 GlaxoSmithKline Plc 62 Idera Pharmaceuticals, Inc. 63 ImmuNext, Inc. 64 Immunomedics, Inc. 65 Incyte Corporation 66 Kadmon Corporation, LLC 67 Kamada Ltd. 68 Kiadis Pharma N.V. 69 Kymab Limited 70 Kyorin Pharmaceutical Co., Ltd. 71 MacroGenics, Inc. 72 Mallinckrodt Plc 73 Medsenic 74 Mesoblast Limited 75 Millennium Pharmaceuticals Inc 76 Neopharm Ltd. 77 Nohla Therapeutics Inc. 78 Novartis AG 79 OncoImmune, Inc. 80 OSE Immunotherapeutics 81 Pharmicell Co., Ltd. 82 Pluristem Therapeutics Inc. 83 REGiMMUNE Corporation 84 Rigel Pharmaceuticals, Inc. 85 Sarepta Therapeutics, Inc. 86 Seattle Genetics, Inc. 87 Seres Therapeutics, Inc. 88 Sigmoid Pharma Limited 89 Spherium Biomed S.L. 90 Taiga Biotechnologies, Inc. 91 Takeda Pharmaceutical Company Limited 92 Targazyme, Inc. 93 Therapix Biosciences Ltd 94 Tobira Therapeutics, Inc. 95 Vault Pharma Inc. 96 Xenikos B.V. 97 ZIOPHARM Oncology, Inc. 98 Bone Marrow Transplant Rejection - Therapeutics Assessment 99 Assessment by Monotherapy Products 99 Assessment by Combination Products 100 Assessment by Target 101 Assessment by Mechanism of Action 105 Assessment by Route of Administration 109 Assessment by Molecule Type 111 Drug Profiles 113 abatacept - Drug Profile 113 AbGn-168H - Drug Profile 118 AGS-499 - Drug Profile 120 aldesleukin - Drug Profile 121 Alecmestencel-L - Drug Profile 123 alpha-1 proteinase inhibitor (human) - Drug Profile 124 ALXN-1007 - Drug Profile 129 AMX-342 - Drug Profile 130 anti-thymocyte globulin (rabbit) - Drug Profile 131 Antibodies to Antagonize CD40L for Autoimmune Diseases and GVHD - Drug Profile 133 Antisense Oligonucleotide to Inhibit TLRs for Systemic Lupus Erythematosus and Graft Versus Host Disease - Drug Profile 134 ARGX-115 - Drug Profile 135 arsenic trioxide - Drug Profile 136 ATIR-101 - Drug Profile 137 BCT-200 - Drug Profile 141 begelomab - Drug Profile 142 Biologic to Activate IL-2 for Graft Versus Host Disease - Drug Profile 143 Biologics for Graft Versus Host Disease - Drug Profile 144 bortezomib - Drug Profile 145 BPX-501 - Drug Profile 153 BR-05001 - Drug Profile 157 brentuximab vedotin - Drug Profile 158 budesonide - Drug Profile 182 cannabidiol - Drug Profile 185 CAP-2003 - Drug Profile 186 CBLB-612 - Drug Profile 187 CD-24Fc - Drug Profile 189 Cell Therapy for Graft Versus Host Disease - Drug Profile 190 Cell Therapy for Graft-Versus Host Disease - Drug Profile 191 Cellgram for Graft Versus Host Disease - Drug Profile 192 Cellular Immunotherapy for Acute Graft Versus Host Disease - Drug Profile 193 Cellular Immunotherapy for Autoimmune Diseases and Transplantation - Drug Profile 194 Cellular Immunotherapy for Bone Marrow Transplantation - Drug Profile 196 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 197 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 198 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 199 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 200 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 201 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 202 Cellular Immunotherapy for Graft Versus Host Disease - Drug Profile 203 Cellular Immunotherapy for Graft Versus Host Disease and Multiple Myeloma - Drug Profile 204 cenicriviroc mesylate - Drug Profile 205 CGEN-15001 - Drug Profile 212 CRCBT-080004 - Drug Profile 215 CX-01 - Drug Profile 216 cyclosporine CR + cyclosporine IR - Drug Profile 218 CYP-001 - Drug Profile 219 entospletinib - Drug Profile 220 F-652 - Drug Profile 222 FR-104 - Drug Profile 223 Ha-7 - Drug Profile 226 ibrutinib - Drug Profile 227 ImmuneSafe - Drug Profile 252 ImmuStem - Drug Profile 253 IMO-8400 - Drug Profile 254 IT-603 - Drug Profile 260 IT-901 - Drug Profile 261 itacitinib adipate - Drug Profile 262 KD-025 - Drug Profile 265 KRP-203 - Drug Profile 269 KY-1005 - Drug Profile 271 MAX-16H5 - Drug Profile 272 MesoStem - Drug Profile 273 methoxsalen - Drug Profile 274 MGD-010 - Drug Profile 276 milatuzumab - Drug Profile 278 Monoclonal Antibody to Inhibit CD3 for Cardiovascular, CNS, Gastrointestinal, Immunological, Infectious and Metabolic Diseases - Drug Profile 281 MPC-CBE - Drug Profile 283 natalizumab - Drug Profile 285 obinutuzumab - Drug Profile 290 OCU-300 - Drug Profile 297 Oligonucleotide to Inhibit NFAT1 for GVHD - Drug Profile 298 panobinostat - Drug Profile 299 PF-05285401 - Drug Profile 307 PLXR-18 - Drug Profile 318 ponesimod - Drug Profile 325 Preimplantation Factor - Drug Profile 328 PRO-140 - Drug Profile 329 ProTmune - Drug Profile 337 R-348 - Drug Profile 339 Recombinant Protein for Graft Versus Host Disease and Autoimmune Disorders - Drug Profile 341 Recombinant Protein to Antagonize CCR8 for Graft Versus Host Disease and Multiple Sclerosis - Drug Profile 342 Recombinant Protein to Inhibit ILT3 for Graft Versus Host Disease - Drug Profile 343 remestemcel-L - Drug Profile 344 reparixin - Drug Profile 349 RGI-2001 - Drug Profile 352 RO-2959 - Drug Profile 354 rovalpituzumab tesirine - Drug Profile 355 ruxolitinib phosphate - Drug Profile 357 S-Graft - Drug Profile 370 SER-155 - Drug Profile 371 Small Molecule for Autoimmune Disorders, Graft Versus Host Disease and Hemophagocytic Lymphohistiocytosis - Drug Profile 372 Small Molecule to Inhibit Protein Kinase C Theta for Immunological Disorders and Multiple Sclerosis - Drug Profile 373 Small Molecules to Inhibit Perforin for Bone Marrow Transplantation - Drug Profile 374 Small Molecules to Inhibit SHIP1 for Oncology and Immunology - Drug Profile 375 Small Molecules to Selectively Inhibit ROCK2 for Autoimmune Disorders - Drug Profile 376 sonidegib phosphate - Drug Profile 377 SP-12008 - Drug Profile 382 SYGN-305 - Drug Profile 383 Synthetic Peptide to Antagonize VIPR for Cytomegalovirus Infection and Graft Versus Host Disease - Drug Profile 384 T-Guard - Drug Profile 385 TBX-1400 - Drug Profile 387 TM-5509 - Drug Profile 388 TZ-101 - Drug Profile 389 vedolizumab - Drug Profile 392 VPI-101 - Drug Profile 397 ZL-1101 - Drug Profile 398 Bone Marrow Transplant Rejection - Dormant Projects 399 Bone Marrow Transplant Rejection - Discontinued Products 405 Bone Marrow Transplant Rejection - Product Development Milestones 406 Featured News & Press Releases 406 Appendix 418 Methodology 418 Coverage 418 Secondary Research 418 Primary Research 418 Expert Panel Validation 418 Contact Us 418 Disclaimer 419
List of Tables
Number of Products under Development for Bone Marrow Transplant Rejection, H2 2016 20 Number of Products under Development for Bone Marrow Transplant Rejection - Comparative Analysis, H2 2016 21 Number of Products under Development by Companies, H2 2016 22 Number of Products under Development by Companies, H2 2016 (Contd..1) 23 Number of Products under Development by Companies, H2 2016 (Contd..2) 24 Number of Products under Development by Companies, H2 2016 (Contd..3) 25 Number of Products under Development by Companies, H2 2016 (Contd..4) 26 Number of Products under Investigation by Universities/Institutes, H2 2016 28 Comparative Analysis by Late Stage Development, H2 2016 29 Comparative Analysis by Clinical Stage Development, H2 2016 30 Comparative Analysis by Early Stage Development, H2 2016 31 Comparative Analysis by Unknown Stage Development, H2 2016 32 Products under Development by Companies, H2 2016 33 Products under Development by Companies, H2 2016 (Contd..1) 34 Products under Development by Companies, H2 2016 (Contd..2) 35 Products under Development by Companies, H2 2016 (Contd..3) 36 Products under Development by Companies, H2 2016 (Contd..4) 37 Products under Development by Companies, H2 2016 (Contd..5) 38 Products under Investigation by Universities/Institutes, H2 2016 39 Products under Investigation by Universities/Institutes, H2 2016 (Contd..1) 40 Bone Marrow Transplant Rejection - Pipeline by AbbVie Inc, H2 2016 41 Bone Marrow Transplant Rejection - Pipeline by AbGenomics International, Inc., H2 2016 42 Bone Marrow Transplant Rejection - Pipeline by Actelion Ltd, H2 2016 43 Bone Marrow Transplant Rejection - Pipeline by Alexion Pharmaceuticals Inc, H2 2016 44 Bone Marrow Transplant Rejection - Pipeline by Amunix Operating Inc. , H2 2016 45 Bone Marrow Transplant Rejection - Pipeline by Apceth GmbH & Co. KG, H2 2016 46 Bone Marrow Transplant Rejection - Pipeline by arGEN-X BV, H2 2016 47 Bone Marrow Transplant Rejection - Pipeline by Athersys, Inc., H2 2016 48 Bone Marrow Transplant Rejection - Pipeline by Bellicum Pharmaceuticals, Inc., H2 2016 49 Bone Marrow Transplant Rejection - Pipeline by Bio-Cancer Treatment International Limited, H2 2016 50 Bone Marrow Transplant Rejection - Pipeline by Biogen Inc, H2 2016 51 Bone Marrow Transplant Rejection - Pipeline by Boryung Pharmaceutical Co., Ltd., H2 2016 52 Bone Marrow Transplant Rejection - Pipeline by Bristol-Myers Squibb Company, H2 2016 53 Bone Marrow Transplant Rejection - Pipeline by Cantex Pharmaceuticals, Inc., H2 2016 54 Bone Marrow Transplant Rejection - Pipeline by Capricor Therapeutics, Inc., H2 2016 55 Bone Marrow Transplant Rejection - Pipeline by Cell Source, Inc., H2 2016 56 Bone Marrow Transplant Rejection - Pipeline by Cell2B S.A. , H2 2016 57 Bone Marrow Transplant Rejection - Pipeline by CellECT Bio, Inc., H2 2016 58 Bone Marrow Transplant Rejection - Pipeline by Cleveland BioLabs, Inc., H2 2016 59 Bone Marrow Transplant Rejection - Pipeline by Compugen Ltd., H2 2016 60 Bone Marrow Transplant Rejection - Pipeline by Cynata Therapeutics Limited, H2 2016 61 Bone Marrow Transplant Rejection - Pipeline by Cytodyn Inc., H2 2016 62 Bone Marrow Transplant Rejection - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 63 Bone Marrow Transplant Rejection - Pipeline by Dr. Falk Pharma GmbH, H2 2016 64 Bone Marrow Transplant Rejection - Pipeline by Escape Therapeutics, Inc., H2 2016 65 Bone Marrow Transplant Rejection - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 66 Bone Marrow Transplant Rejection - Pipeline by Fate Therapeutics, Inc., H2 2016 67 Bone Marrow Transplant Rejection - Pipeline by Generon (Shanghai) Corporation Ltd., H2 2016 68 Bone Marrow Transplant Rejection - Pipeline by Gilead Sciences, Inc., H2 2016 69 Bone Marrow Transplant Rejection - Pipeline by GlaxoSmithKline Plc, H2 2016 70 Bone Marrow Transplant Rejection - Pipeline by Idera Pharmaceuticals, Inc., H2 2016 71 Bone Marrow Transplant Rejection - Pipeline by ImmuNext, Inc., H2 2016 72 Bone Marrow Transplant Rejection - Pipeline by Immunomedics, Inc., H2 2016 73 Bone Marrow Transplant Rejection - Pipeline by Incyte Corporation, H2 2016 74 Bone Marrow Transplant Rejection - Pipeline by Kadmon Corporation, LLC, H2 2016 75 Bone Marrow Transplant Rejection - Pipeline by Kamada Ltd., H2 2016 76 Bone Marrow Transplant Rejection - Pipeline by Kiadis Pharma N.V., H2 2016 77 Bone Marrow Transplant Rejection - Pipeline by Kymab Limited, H2 2016 78 Bone Marrow Transplant Rejection - Pipeline by Kyorin Pharmaceutical Co., Ltd., H2 2016 79 Bone Marrow Transplant Rejection - Pipeline by MacroGenics, Inc., H2 2016 80 Bone Marrow Transplant Rejection - Pipeline by Mallinckrodt Plc, H2 2016 81 Bone Marrow Transplant Rejection - Pipeline by Medsenic, H2 2016 82 Bone Marrow Transplant Rejection - Pipeline by Mesoblast Limited, H2 2016 83 Bone Marrow Transplant Rejection - Pipeline by Millennium Pharmaceuticals Inc, H2 2016 84 Bone Marrow Transplant Rejection - Pipeline by Neopharm Ltd., H2 2016 85 Bone Marrow Transplant Rejection - Pipeline by Nohla Therapeutics Inc., H2 2016 86 Bone Marrow Transplant Rejection - Pipeline by Novartis AG, H2 2016 87 Bone Marrow Transplant Rejection - Pipeline by OncoImmune, Inc., H2 2016 88 Bone Marrow Transplant Rejection - Pipeline by OSE Immunotherapeutics, H2 2016 89 Bone Marrow Transplant Rejection - Pipeline by Pharmicell Co., Ltd., H2 2016 90 Bone Marrow Transplant Rejection - Pipeline by Pluristem Therapeutics Inc., H2 2016 91 Bone Marrow Transplant Rejection - Pipeline by REGiMMUNE Corporation, H2 2016 92 Bone Marrow Transplant Rejection - Pipeline by Rigel Pharmaceuticals, Inc., H2 2016 93 Bone Marrow Transplant Rejection - Pipeline by Sarepta Therapeutics, Inc., H2 2016 94 Bone Marrow Transplant Rejection - Pipeline by Seattle Genetics, Inc., H2 2016 95 Bone Marrow Transplant Rejection - Pipeline by Seres Therapeutics, Inc., H2 2016 96 Bone Marrow Transplant Rejection - Pipeline by Sigmoid Pharma Limited, H2 2016 97 Bone Marrow Transplant Rejection - Pipeline by Spherium Biomed S.L., H2 2016 98 Bone Marrow Transplant Rejection - Pipeline by Taiga Biotechnologies, Inc., H2 2016 99 Bone Marrow Transplant Rejection - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 100 Bone Marrow Transplant Rejection - Pipeline by Targazyme, Inc., H2 2016 101 Bone Marrow Transplant Rejection - Pipeline by Therapix Biosciences Ltd, H2 2016 102 Bone Marrow Transplant Rejection - Pipeline by Tobira Therapeutics, Inc., H2 2016 103 Bone Marrow Transplant Rejection - Pipeline by Vault Pharma Inc., H2 2016 104 Bone Marrow Transplant Rejection - Pipeline by Xenikos B.V., H2 2016 105 Bone Marrow Transplant Rejection - Pipeline by ZIOPHARM Oncology, Inc., H2 2016 106 Assessment by Monotherapy Products, H2 2016 107 Assessment by Combination Products, H2 2016 108 Number of Products by Stage and Target, H2 2016 110 Number of Products by Stage and Mechanism of Action, H2 2016 114 Number of Products by Stage and Route of Administration, H2 2016 118 Number of Products by Stage and Molecule Type, H2 2016 120 Bone Marrow Transplant Rejection - Dormant Projects, H2 2016 406 Bone Marrow Transplant Rejection - Dormant Projects (Contd..1), H2 2016 407 Bone Marrow Transplant Rejection - Dormant Projects (Contd..2), H2 2016 408 Bone Marrow Transplant Rejection - Dormant Projects (Contd..3), H2 2016 409 Bone Marrow Transplant Rejection - Dormant Projects (Contd..4), H2 2016 410 Bone Marrow Transplant Rejection - Dormant Projects (Contd..5), H2 2016 411 Bone Marrow Transplant Rejection - Discontinued Products, H2 2016 412
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
